WuXi Biologics (2269.HK), a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has received EMA GMP certificates for the production of Trogarzo at its cGMP Drug Substance and Drug Product manufacturing facilities in Wuxi city and its cGMP cell banking facilities in Shanghai, it was reported yesterday.
The product is developed by TaiMed Biologics and marketed in the United States and EU by Theratechnologies.
WuXi Biologics said that the certification further endorses its systems and solid reputation as a leading global bio-manufacturing player.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML